Outcomes of Once-Daily ICS/LABA/LAMA Plus PRN Respiratory Therapy Treatments in Hospitalized Patients With COPD Exacerbations

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

April 1, 2022

Primary Completion Date

August 30, 2023

Study Completion Date

September 30, 2023

Conditions
Copd
Interventions
DRUG

TRELEGY ELLIPTA 100Mcg-62.5Mcg-25Mcg/Actuation Powder for Inhalation

TRELEGY ELLIPTA (fluticasone furoate 100 mcg, umeclidinium 62.5 mcg, and vilanterol 25 mcg inhalation powder)

Trial Locations (1)

75246

Baylor Scott & White Health Research Institute, Dallas

Sponsors
All Listed Sponsors
lead

Baylor Research Institute

OTHER